IN8bio Investor Relations Material
Latest events
Study Result
IN8bio
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from IN8bio Inc
Access all reports
IN8bio Inc., previously known as Incysus Therapeutics, is a clinical-stage biopharmaceutical company focused on the development of innovative gamma-delta T cell therapies for cancer treatment. Their portfolio includes lead product candidates in various phases of clinical trials, targeting conditions such as glioblastoma and acute leukemia, alongside a broad spectrum of preclinical programs aimed at solid tumors. Utilizing their proprietary DeltEx platform, IN8bio develops both autologous and allogeneic gamma-delta T cell therapies, leveraging the unique properties of gamma-delta T cells to differentiate between healthy and diseased tissues. The company was established in 2016 and is headquartered in New York, New York, with its primary scientific operations based in Birmingham, Alabama. Its shares are listed on the NASDAQ.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
INAB
Country
🇺🇸 United States